Welcome to our dedicated page for SINOVAC BIOTECH SEC filings (Ticker: SVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sinovac Biotech Ltd. filings document the company’s foreign private issuer reporting for a China-based vaccine developer, including Form 20-F annual reporting and Form 6-K current reports. The disclosures cover vaccine operations, consolidated financial statements, interim results, product portfolio context and pipeline categories such as combination vaccines, recombinant protein vaccines, mRNA technologies and antibodies.
Recent filings also record auditor engagement and annual-report correction matters, Nasdaq listing-compliance notices tied to filing deadlines, and board governance actions, including director independence, committee appointments and proceedings over board composition. These filings frame Sinovac’s capital-market reporting, governance controls and regulatory status as a Nasdaq issuer.
Schedule 13D/A Amendment No. 6 filed by Dr. Weidong Yin discloses continued beneficial ownership of 6,359,500 Sinovac Biotech (SVA) common shares, representing 8.85 % of the 71.86 million shares outstanding as reported in the company’s 2023 Form 20-F.
The amendment adds one material update: on 10 July 2025 Sinovac announced a newly constituted 10-member Board of Directors that now includes Dr. Yin. He has accepted the appointment and intends to participate in the issuer’s future governance. Aside from this governance change, Dr. Yin states he currently has no specific plans that would trigger any of clauses (a)–(j) of Item 4 (e.g., mergers, asset sales, recapitalisations). He continues conversations with other shareholders on governance and value-enhancing matters but expressly disclaims acting as a group.
- Ownership structure: Sole voting and dispositive power over the entire 6.36 million-share position; no shared power disclosed.
- Funding source: Personal funds (“PF”).
- Citizenship: China.
No new contracts or arrangements regarding the securities are reported beyond those described in Item 4. The filing is signed by Dr. Yin on 14 July 2025.
Vivo Capital VIII, LLC and Vivo Capital IX, LLC filed Amendment No. 6 to their Schedule 13D regarding Sinovac Biotech Ltd. (NASDAQ: SVA) on 11 July 2025. The filing updates share ownership and details an ongoing proxy and litigation battle over control of Sinovac’s board.
Ownership: Vivo Capital VIII reports 1,361,236 common shares (1.9%); Vivo Capital IX reports 4,541,764 common shares (6.3%), based on 71,860,702 shares outstanding, for a combined 8.2% economic interest. Both entities have shared voting and dispositive power over their respective holdings.
Purpose of transaction: The amendment narrates events surrounding a Special Meeting called for 8 July 2025. Sinovac sought a court injunction to exclude Vivo and another investor from voting. Vivo opposed the injunction; the Eastern Caribbean Court of Appeal stayed enforcement on 8 July, enabling Vivo to vote its shares by proxy in favor of SAIF’s director slate (including Mr. Shan Fu). Sinovac disclosed on 10 July 2025 that the SAIF-backed slate was elected and Mr. Fu joined the board.
Vivo states it will continue to engage with other shareholders and pursue actions under Item 4 of Schedule 13D, such as influencing board composition, dividend policy, auditor replacement, SEC filing compliance, and a potential NASDAQ relisting. Vivo also references multiple legal proceedings, including a 30 June 2025 U.S. District Court injunction compelling disclosure from shareholders linked to Sinovac’s chairman.
Exhibits: Two press releases (2 July 2025 and 9 July 2025) describing the legal developments are incorporated by reference.
Implications for investors: The filing confirms an activist position totaling 8.2% of Sinovac’s equity and outlines continuing efforts to reshape governance. While successful in electing a new board slate, persistent litigation indicates ongoing uncertainty around corporate control and future strategic direction.